18 and older, female only, with Endometrial Cancer or Carcinosarcoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Overall Response Rate/ORR of ParticipantsPrimary· </= 24 weeks from the start of treatment
ORR = Compete Response (CR) + Partial Response (PR) by RECIST v 1.1 \</= 24 weeks from the start of treatment
Group
Value
95% CI
Stage 1
1
Stage 1
15
Adverse events — posted to ClinicalTrials.gov
Time frame: 24 weeks from end of treatment, up to 48 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study is being done to test the drug ZW25 and look at whether this drug is effective in women with HER2-overexpressed endometrial cancer or carcinosarcoma that has been treated in the past.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726
· Phase 1
· recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P
· recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH
· Phase 2
· recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
· Phase 2, PHASE3
· recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer
· recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer
· Phase 2
· recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery
· Phase 3
· recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
· Phase 2
· recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term
· Phase 2
· recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 22 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04513665.